Anti-CD38 molecules as part of highly effective combination regimens have been approved in both newly diagnosed and relapsed/refractory patients and have significantly changed the myeloma treatment landscape in the recent years. Another strategy is to use antibodies that bind both to a molecule on ...
Recent Findings Three monoclonal antibodies (daratumumab, isatuximab, elotuzumab) and one anti-BCMA (B-cell maturation antigen) antibody-drug conjugate (belantamab mafodotin) have been approved by the FDA in the last 5 years for the treatment of multiple myeloma. There are many ongoing ...
Daratumumab: the first anti-CD38 monoclonal antibody for the treatment of multiple myelomaCyrille TouzeauBenjamin HébraudXavier Leleu
CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myelomaCD26, a 110-kDa transmembrane glycoprotein that is expressed on several tumor cells including malignant lymphoma, has been implicated in tumorigenesis: however, little is known regarding its ...
mechanisms for GPRC5D. However, the specific binding interface and molecular interaction details between GPRC5D and scFv may potentially expedite the development of targeted antibody therapies for GPRC5D, leveraging computation and AI-aided approaches, to bring hope for the treatment of multiple myeloma...
High expression on multiple myeloma (MM) cells and limited expression on normal cells makes CD38 an ideal target for the treatment of MM patients. Two monoclonal antibodies directed at CD38, isatuximab and daratumumab, are available for use in patients with relapsed and/or refractory MM (RRMM)...
Another caveat when considering using CAR T-cell therapy in patients is the length of time it takes to prepare the treatment. “Right now, the challenge with CAR T-cell therapy is the time it takes to collect the T cells and the wait for the product to come back,” Usmani said. “Man...
Despite recent advances in the treatment of multiple myeloma, new agents are still needed to improve the outcome for patients. The established success of monoclonal antibodies in the treatment of some cancers has promoted interest in developing antibody-based therapies for multiple myeloma. Efforts have...
“We believe Sarclisa has the potential to become the anti-CD38 of choice for the treatment of multiple myeloma. We look forward to seeing the results from future clinical trials to understand the impact of Sarclisa in earlier stages of disease.” ...
Recombinant human erythropoietin administered after peripheral blood stem cell transplantation (PBSCT) has been ineffective for the treatment of anemia. We... M Martino,E Oliva,G Console,... - 《Supportive Care in Cancer》 被引量: 19发表: 2005年 Multiple Myeloma Monoclonal antibody purged autologou...